Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

8.625 -0.275 (-3.09%)
Streaming Delayed Price Updated: 1:53 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
News headline image
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
What's Next: Vir Biotechnology's Earnings Preview ↗
 
Via Benzinga
News headline image
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? ↗
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens. 
Via Benzinga
News headline image
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
What You Missed On Wall Street This Past Friday ↗
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
News headline image
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
From Vir Biotechnology Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024 ↗
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
News headline image
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
News headline image
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets ↗
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
News headline image
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? ↗
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.